- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00069082
Intranasal Civamide for Episodic Cluster Headache
June 8, 2011 updated by: Winston Laboratories
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Evaluation of Civamide (Zucapsaicin) Nasal Solution in the Treatment of Episodic Cluster Headache
This is a 49-day study to evaluate the effectiveness of Intranasal Civamide (Zucapsaicin) in the treatment of an episodic cluster headache period compared to placebo (medically inactive substance which does not contain any active ingredients).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States
- San Francisco Clinical Research Center
-
Santa Monica, California, United States
- California Medical Clinic for Headache
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Neurology and Headache Clinic
-
-
Illinois
-
Chicago, Illinois, United States
- Diamond Headache Clinic
-
-
New York
-
New York, New York, United States
- New York Headache Center
-
-
Ohio
-
Cleveland, Ohio, United States
- Cleveland Clinic Foundation
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
- At least 2 year history of episodic cluster headache (meeting IHS criteria)
- At least 2 previous episodes
- Expected duration of cluster period is at least 6 weeks but not longer than 24 weeks
- At least 1 but not more than 8 headaches on each of the 3 days immediately prior to treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Civamide
Nasal Solution 0.01%
|
Nasal Solution 0.01%
|
|
Placebo Comparator: Placebo
Placebo nasal solution with sodium chloride 10%
|
Nasal Solution 10%
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Scott B Phillips, MD, Winston Laboratories
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Primary Completion (Actual)
January 1, 2004
Study Completion (Actual)
January 1, 2004
Study Registration Dates
First Submitted
September 15, 2003
First Submitted That Met QC Criteria
September 15, 2003
First Posted (Estimate)
September 16, 2003
Study Record Updates
Last Update Posted (Estimate)
June 10, 2011
Last Update Submitted That Met QC Criteria
June 8, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WL-1001-02-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Episodic Cluster Headache
-
Diamond Headache ClinicGlaxoSmithKlineUnknownEpisodic Cluster Headache | Chronic Cluster HeadacheUnited States
-
Eli Lilly and CompanyCompletedEpisodic Cluster Headache | Chronic Cluster HeadacheSpain, United States, Finland, Germany, United Kingdom, Belgium, France, Denmark, Italy, Netherlands, Canada, Greece
-
Winston LaboratoriesNot yet recruitingEpisodic Cluster Headache
-
Hospices Civils de LyonNot yet recruitingCluster Headache, Episodic
-
H. Lundbeck A/SCompletedCluster Headache, EpisodicSpain, United States, Germany, Portugal, Italy, Netherlands, Finland, Belgium, Czechia, Denmark, France, Georgia, Russian Federation, United Kingdom, Greece, Estonia, Japan, Norway, Sweden
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedEpisodic Cluster HeadacheUnited States, Australia, Finland, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom, Canada
-
Eli Lilly and CompanyCompletedEpisodic Cluster HeadacheItaly, United States, Canada, Belgium, Denmark, Finland, France, Germany, Spain, United Kingdom, Netherlands, Greece
-
Center Laboratories, Inc.TerminatedEpisodic Cluster HeadacheUnited Kingdom
-
Winston LaboratoriesCompletedEpisodic Cluster HeadacheUnited States
-
Leiden University Medical CenterNetherlands Brain Foundation; Innovatiefonds ZorgverzekeraarsCompletedCluster Headache, Episodic | Greater Occipital Nerve InjectionNetherlands
Clinical Trials on Civamide (Zucapsaicin)
-
Winston LaboratoriesCompletedPostherpetic NeuralgiaUnited States, Canada
-
Winston LaboratoriesCompletedOsteoarthritis of the Knee
-
Winston LaboratoriesCompletedEpisodic Cluster HeadacheUnited States
-
Winston LaboratoriesCompleted
-
Winston LaboratoriesTerminated
-
Winston LaboratoriesTerminatedPostherpetic NeuralgiaUnited States
-
Winston LaboratoriesCompleted
-
Winston LaboratoriesNot yet recruitingEpisodic Cluster Headache